Healthcare Strategies Group provides a unique blend of strategic advisory services and operational business development and general management support to the precision medicine and broader life science and medical technology communities. The company’s core advisory services include general management and fundraising/business planning support for SMEs, together with commercial strategy development, operational business development, and market access support to established corporates.
The founder, Dr. Iain Miller, has extensive international experience, having split his career between the US and the EU. His client and broader experience base spans GE Healthcare, Biomerieux, J&J, Amgen, Sanofi, Philips, Celgene, Myriad Genetics, Guardant Health, Oxford Immnotec, Abbott Diagnostics and InnovateUK, in addition to various SMEs and investor groups. In addition to his 20-year US experience, Dr. Miller has worked extensively in the UK and EU marketplace, including major market access policy projects with European thought leaders. He is also a founding Board member of the European Personalized Medicine Association and has been very active in the UK stratified medicine and broader med-tech ecosystems. Within the UK, Iain sat until recently on the NICE Technology Appraisal Committee which reviews drugs and companion test products and also frequently serves as an assessor for Innovate UK, the leading funder of UK life science innovation. Healthcare Strategies Group is based in London, where Dr. Miller and his associates frequently provide market bridging services between the US and the EU, including on-the-ground UK / EU market development for US companies and US market development support for UK-based companies.
Please click here for more information on the services provided by Healthcare Strategies Group or here for more information on our clients and illustrative projects. Detailed information on the Founder and Team can be found here . Information on Company News and Events, including upcoming publications and links to our thought leadership articles, can be found here .
****** Latest News:
July 2020: Dr Miller joins Board of Directors of Presymptom Health, a spinout Venture of the Uk Defence Science & Technologies Labs focus on early diagnosis of disease
December 2019: New article published in Journal of Precision Medicine: Acceleration of Adoption of High Complexity Precision Diagnostics by Global Public Healthcare Systems
November 8, 2019: Dr. Miller to present at Innovation in Healthcare: Personalized & Regenerative Medicine conference in Barcelona, Spain
January 2018 – present: Dr. Miller agrees to serve as part-time and Director of the Board of SAW Diagnostics. SAW Dx is emerging Point-Of-Care company SAW Diagnostics (www.sawdx.com). Dr. Miller will continue to serve Healthcare Strategies Group’s clients alongside his role at SAW Dx
May 10, 2017. Dr. Miller article “Realizing the potential of Precision Oncology” publishes in the Journal of Precision Medicine. Available here.
January 3, 2017. Dr. Miller article “Considerations for the Successful Development of Precision Immuno-Oncology Therapies and Their Companion Tests” publishes in Genetic Engineering News. Available here.
August 9, 2016. Dr Miller’s new commentary article “The evolution of high complexity companion testing for targeted and immuno-oncology” publishes in the journal Personalized Medicine. Free pdf download available here.
September 2016 Dr. Miller to present on Diagnostic Market Access and Commercialization Strategy at the 1st International Congress focusing on Molecular Diagnostic Technologies in Barcelona, Spain and at the Precision Medicine Congress in London
July 11-12 2016 Dr. Miller makes presentation on Commercialization Strategy for Companion Diagnostics and moderates expert panel at the Precision Medicine Forum in London